Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2014 | Research

An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer

Authors: Xin Zhou, Xiaping Wang, Zebo Huang, Lei Xu, Wei Zhu, Ping Liu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Abstract

Background

Breast cancer patients with positive estrogen receptor (ER) have a better prognosis. However, no prognostic miRNA signature was reported in the ER-positive breast cancer. The aim of the study was to identify and assess the prognostic significance of a miRNA signature in ER-positive breast cancer.

Methods

Two cohorts from The Cancer Genome Atlas (TCGA) dataset were used as training (n =596) and testing set (n =319). Differential expression profiling was identified in the training set. And the prognostic value of the miRNA signature was then assessed in the two cohorts.

Results

A total of 14 miRNAs were observed to be associated with the status of ER by significance analysis of microarrays (SAM) in the training set. Patients were characterized as high score or low score group according to the calculated risk scores from each miRNA. And patients in high score group had worse overall survival compared with those in low score group both in the training and testing set.

Conclusions

Our study revealed a miRNA signature including 14 miRNAs associated with ER status which could act as a prognostic marker in ER-positive breast cancer.

Available only for authorised users

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27: 1160-1167. 10.1200/JCO.2008.18.1370PubMedCentralCrossRefPubMed

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98: 10869-10874. 10.1073/pnas.191367098PubMedCentralCrossRefPubMed

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR: Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12: 1294-1300. 10.1038/nm1491CrossRefPubMed

Yin ZQ, Liu JJ, Xu YC, Yu J, Ding GH, Yang F, Tang L, Liu BH, Ma Y, Xia YW, Lin XL, Wang HX: A 41-gene signature derived from breast cancer stem cells as a predictor of survival. J Exp Clin Cancer Res 2014, 33: 49. 10.1186/1756-9966-33-49PubMedCentralCrossRefPubMed

Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, Chen L: Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res 2014, 33: 14. 10.1186/1756-9966-33-14PubMedCentralCrossRefPubMed

Zhang X, Min J, Wang Y, Li Y, Li H, Liu Q, Liang X, Mu P: RABEX-5 plays an oncogenic role in breast cancer by activating MMP-9 pathway. J Exp Clin Cancer Res 2013, 32: 52. 10.1186/1756-9966-32-52PubMedCentralCrossRefPubMed

Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 2011, 29: 1531-1538. 10.1200/JCO.2010.30.3677PubMedCentralCrossRefPubMed

Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM: Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer 2014, 110: 565-572. 10.1038/bjc.2013.756PubMedCentralCrossRefPubMed

Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC: Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013, 31: 1726-1731. 10.1200/JCO.2012.44.8027PubMedCentralCrossRefPubMed

10.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295: 2492-2502. 10.1001/jama.295.21.2492CrossRefPubMed

11.

Nishio M, Naoi Y, Tsunashima R, Nakauchi C, Kagara N, Shimoda M, Shimomura A, Maruyama N, Shimazu K, Kim SJ, Noguchi S: 72-Gene classifier for predicting prognosis of estrogen receptor-positive and node-negative breast cancer patients using formalin-fixed, paraffin-embedded tumor tissues. Clin Breast Cancer 2013, 14: e73-80. 10.1016/j.clbc.2013.11.006CrossRefPubMed

12.

Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75: 843-854. 10.1016/0092-8674(93)90529-YCrossRefPubMed

13.

Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120: 15-20. 10.1016/j.cell.2004.12.035CrossRefPubMed

14.

Carrington JC, Ambros V: Role of microRNAs in plant and animal development. Science 2003, 301: 336-338. 10.1126/science.1085242CrossRefPubMed

15.

Suarez Y, Sessa WC: MicroRNAs as novel regulators of angiogenesis. Circ Res 2009, 104: 442-454. 10.1161/CIRCRESAHA.108.191270PubMedCentralCrossRefPubMed

16.

Xu P, Guo M, Hay BA: MicroRNAs and the regulation of cell death. Trends Genet 2004, 20: 617-624. 10.1016/j.tig.2004.09.010CrossRefPubMed

17.

Bartel DP, Chen CZ: Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004, 5: 396-400. 10.1038/nrg1328CrossRefPubMed

18.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH: Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 2013, 14: 1295-1306. 10.1016/S1470-2045(13)70491-1CrossRefPubMed

19.

Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J: Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 2012, 13: 633-641. 10.1016/S1470-2045(12)70102-XCrossRefPubMed

20.

Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX, Zhong L: Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res 2013, 32: 21. 10.1186/1756-9966-32-21PubMedCentralCrossRefPubMed

21.

Wang Q, Li P, Li A, Jiang W, Wang H, Wang J, Xie K: Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 2012, 31: 97. 10.1186/1756-9966-31-97PubMedCentralCrossRefPubMed

22.

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L: Mutational landscape and significance across 12 major cancer types. Nature 2013, 502: 333-339. 10.1038/nature12634PubMedCentralCrossRefPubMed

23.

Volinia S, Croce CM: Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A 2013, 110: 7413-7417. 10.1073/pnas.1304977110PubMedCentralCrossRefPubMed

24.

Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007, 3: 11-17.PubMedCentralPubMed

25.

Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang S, Zen K, Ba Y, Zhang CY: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011, 47: 784-791. 10.1016/j.ejca.2010.10.025CrossRefPubMed

26.

DeSantis C, Siegel R, Bandi P, Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 2011, 61: 409-418. 10.3322/caac.20134CrossRefPubMed

27.

Jorns JM, Healy P, Zhao L: Review of estrogen receptor, progesterone receptor, and HER-2/neu immunohistochemistry impacts on treatment for a small subset of breast cancer patients transferring care to another institution. Arch Pathol Lab Med 2013, 137: 1660-1663. 10.5858/arpa.2012-0670-OACrossRefPubMed

28.

Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295: 1658-1667. 10.1001/jama.295.14.1658PubMedCentralCrossRefPubMed

29.

Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H: Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004, 10: 5769-5776. 10.1158/1078-0432.CCR-04-0389CrossRefPubMed

30.

Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole F, Peruzzotti G, Goldhirsch A: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004, 10: 6622-6628. 10.1158/1078-0432.CCR-04-0380CrossRefPubMed

31.

Li R, Qian J, Wang YY, Zhang JX, You YP: Long noncoding RNA profiles reveal three molecular subtypes in Glioma. CNS Neurosci Ther 2014, 20: 339-343. 10.1111/cns.12220CrossRefPubMed

32.

Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009, 11: R27. 10.1186/bcr2257PubMedCentralCrossRefPubMed

33.

Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H: Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res Treat 2011, 130: 331-339. 10.1007/s10549-011-1672-2CrossRefPubMed

34.

Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JP, Janssen EA: Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One 2012, 7: e48692. 10.1371/journal.pone.0048692PubMedCentralCrossRefPubMed

35.

Zhou X, Marian C, Makambi KH, Kosti O, Kallakury BV, Loffredo CA, Zheng YL: MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One 2012, 7: e39011. 10.1371/journal.pone.0039011PubMedCentralCrossRefPubMed

36.

Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin O: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013, 32: 1173-1182. 10.1038/onc.2012.128CrossRefPubMed

37.

Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, Martin F, Crown JP, Jirstrom K, Higgins DG, Gallagher WM, O Connor DP: miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin Cancer Res 2012, 18: 6702-6713. 10.1158/1078-0432.CCR-12-1420CrossRefPubMed

38.

Wang J, Zhao J, Shi M, Ding Y, Sun H, Yuan F, Zou Z: Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PLoS One 2014, 9: e89223. 10.1371/journal.pone.0089223PubMedCentralCrossRefPubMed

39.

Qin Q, Furong W, Baosheng L: Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res 2014, 33: 50. 10.1186/1756-9966-33-50PubMedCentralCrossRefPubMed

40.

Huang L, Dai T, Lin X, Zhao X, Chen X, Wang C, Li X, Shen H, Wang X: MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. Biochem Biophys Res Commun 2012, 425: 127-133. 10.1016/j.bbrc.2012.07.025CrossRefPubMed

41.

Wang J, Zhao H, Tang D, Wu J, Yao G, Zhang Q: Overexpressions of microRNA-9 and microRNA-200c in human breast cancers are associated with lymph node metastasis. Cancer Biother Radiopharm 2013, 28: 283-288. 10.1089/cbr.2012.1293PubMedCentralCrossRefPubMed

Title: An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
Authors: Xin Zhou
Xiaping Wang
Zebo Huang
Lei Xu
Wei Zhu
Ping Liu
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-014-0094-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer

P68 RNA helicase as a molecular target for cancer therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer